✦ LIBER ✦

Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)

✍ Scribed by van den Heuvel-Eibrink, M M; Wiemer, E A C; Kuijpers, M; Pieters, R; Sonneveld, P

Book ID: 110054882
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 80 KB
Volume: 15
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402112

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro-induced resistance to the deoxy

In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene

✍ A. P. A. Stegmann; M. W. Honders; A. Hagemeijer; B. Hoebee; R. Willemze; J. E. L 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 1018 KB

Sequential continuous infusion of fludar

Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

✍ Andrea Camera; Ciro R. Rinaldi; Salvatore Palmieri; Nicola Cantore; Giuseppina M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 159 KB

Phase I trial of gemtuzumab ozogamicin i

Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study

✍ Noriko Usui; Akihiro Takeshita; Chiaki Nakaseko; Nobuaki Dobashi; Hiroyuki Fujit 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

Sequence of administration and methylati

Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)

✍ Iris Middeldorf; Oliver Galm; Rainhardt Osieka; Edgar Jost; James G. Herman; Ste 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 2 views

Results of a phase 2 study of valproic a

Results of a phase 2 study of valproic acid alone or in combination with all-transretinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

✍ Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; C 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 97 KB

A phase I/II study of the MDR modulator

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

✍ Astrid Gruber; Magnus Björkholm; Lorentz Brinch; Stein Evensen; Bengt Gustavsson 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 70 KB